-
Something wrong with this record ?
Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy
T. Lotti, J. Hercogova, G. Fabrizi,
Language English Country England, Great Britain
Document type Journal Article, Review
- MeSH
- Cytokines metabolism therapeutic use MeSH
- Keratinocytes physiology MeSH
- Humans MeSH
- Melanins metabolism MeSH
- Melanocytes physiology MeSH
- Oxidative Stress MeSH
- Signal Transduction MeSH
- Vitiligo drug therapy immunology pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
INTRODUCTION: Vitiligo is a skin disorder characterized by a progressive depigmentation, which is caused by the loss of melanocytes at the cutaneous level. A shift of the immune system with a prevalence of T helper (Th)1/Th17 response instead of a Tregs/Th2 one and may be part of etiology of 10 vitiligo. AREAS COVERED: This review describes the major points of vitiligo onset and shows the cutting-edge results in the field of low-dose medicine in the treatment of dermatologic diseases and, in particular. in vitiligo. In this review on advances in vitiligo pharmacotherapy, the most pertinent recent publications are reported. Electronic databases such as PubMed were searched for terms 'low-dose medicine' or 'low dose and vitiligo' or 'low dose and psoriasis.' EXPERT OPINION: The availability of a systemic treatment for vitiligo, based on the oral administration of low-dose activated signaling molecules represents an opportunity for the dermatologists to overcome some specific pitfalls of currently available therapeutic protocols.
1 University of Rome G Marconi Rome Italy
b 2 Dermatology Clinic Bulovka Dermatology Bulovka Hospital Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16009960
- 003
- CZ-PrNML
- 005
- 20160413113523.0
- 007
- ta
- 008
- 160408s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1517/14656566.2015.1087508 $2 doi
- 024 7_
- $a 10.1517/14656566.2015.1087508 $2 doi
- 035 __
- $a (PubMed)26372794
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lotti, Torello $u a 1 University of Rome "G.Marconi" , Rome, Italy professor@torellolotti.it.
- 245 10
- $a Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy / $c T. Lotti, J. Hercogova, G. Fabrizi,
- 520 9_
- $a INTRODUCTION: Vitiligo is a skin disorder characterized by a progressive depigmentation, which is caused by the loss of melanocytes at the cutaneous level. A shift of the immune system with a prevalence of T helper (Th)1/Th17 response instead of a Tregs/Th2 one and may be part of etiology of 10 vitiligo. AREAS COVERED: This review describes the major points of vitiligo onset and shows the cutting-edge results in the field of low-dose medicine in the treatment of dermatologic diseases and, in particular. in vitiligo. In this review on advances in vitiligo pharmacotherapy, the most pertinent recent publications are reported. Electronic databases such as PubMed were searched for terms 'low-dose medicine' or 'low dose and vitiligo' or 'low dose and psoriasis.' EXPERT OPINION: The availability of a systemic treatment for vitiligo, based on the oral administration of low-dose activated signaling molecules represents an opportunity for the dermatologists to overcome some specific pitfalls of currently available therapeutic protocols.
- 650 _2
- $a cytokiny $x metabolismus $x terapeutické užití $7 D016207
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratinocyty $x fyziologie $7 D015603
- 650 _2
- $a melaniny $x metabolismus $7 D008543
- 650 _2
- $a melanocyty $x fyziologie $7 D008544
- 650 _2
- $a oxidační stres $7 D018384
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a vitiligo $x farmakoterapie $x imunologie $x patologie $7 D014820
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hercogova, Jana $u b 2 Dermatology Clinic Bulovka - Dermatology Bulovka Hospital , Prague Czech Republic.
- 700 1_
- $a Fabrizi, Giuseppe $u c 3 University of Parma - Clinica Dermatologica , Parma, Italy.
- 773 0_
- $w MED00157903 $t Expert opinion on pharmacotherapy $x 1744-7666 $g Roč. 16, č. 16 (2015), s. 2485-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26372794 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160413113607 $b ABA008
- 999 __
- $a ok $b bmc $g 1113389 $s 934328
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 16 $c 16 $d 2485-96 $e 20150915 $i 1744-7666 $m Expert opinion on pharmacotherapy $n Expert Opin Pharmacother $x MED00157903
- LZP __
- $a Pubmed-20160408
